Aptevo Therapeutics (APVO) said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.
The company said nine of ten frontline patients across two studies have now reached remission with the triplet combination of mipletamig, venetoclax, and azacitidine.
Cohort 2 of the trial is nearly fully enrolled, with patients receiving the same dose used in an earlier expansion study, Aptevo said, adding that one patient in the latest cohort progressed and died from causes unrelated to the treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。